D. Rammou

Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study

N. Pavlidis, G. Fountzilas, G. Pentheroudakis, 2004, Anti-cancer drugs.

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

N. Pavlidis, E. Briasoulis, V. Karavasilis, 2004, Cancer Chemotherapy and Pharmacology.

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

P. Beale, J. Wanders, N. Pavlidis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Intravenous Cisplatin-Topotecan Chemotherapy for Three Consecutive Days in Patients with Advanced Solid Tumors: Parallel Topotecan Escalation in Two Fixed Platinum Dosing Schemes

N. Pavlidis, G. Pentheroudakis, D. Mauri, 2005, Chemotherapy.

Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.

N. Pavlidis, G. Pentheroudakis, V. Karavasilis, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.

N. Pavlidis, V. Karavasilis, N Pavlidis, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.